0.1	11. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.			Complete if Known		
Substitute for form 1449A/PTO				Application Number	09/724,685	
INFORMATION DISCLOSURE				Filing Date	11-28-2000	
				First Named Inventor	Steven G. Reed	
STATEMENT BY APPLICANT			ANI	Art Unit	1645	
(Use as many sheets as necessary)		Examiner Name	Rodney P. Swartz			
Sheet	20	of	32	Attorney Docket Number	GSK006C13/CRX411C13	

		FORE	IGN PATENT DO	CUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	T ₆
Irillais		Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY	11	or Relevant Figures Appear	
	277	WO 01/73032 Part 7	10/04/2001	Xu et al.		
	278	WO 01/73032 Part 8	10/04/2001	Xu et al.		
	279	WO 01/73032 Part 9	10/04/2001	Xu et al.		
	280	WO 01/90152 Part 1	11/29/2001	Frudakis et al.		
	281	WO 01/90152 Part 2	11/29/2001	Frudakis et al.		
	282	WO 01/90152 Part 3	11/29/2001	Frudakis et al.		
	283	WO 01/90152 Part 4	11/29/2001	Frudakis et al.		
	284	WO 01/98460 Part 1	12/27/2001	Skeiky et al.		
	285	WO 01/98460 Part 2	12/27/2001	Skeiky et al.		
	286	WO 01/98460 Part 3	12/27/2001	Skeiky et al.		
	287	WO 05/076101	08/18/2005	De Los Santos et al.		
	288	WO 08/107370 Part 1	09/12/2008	Voss		
	289	WO 08/107370 Part 2	09/12/2008	Voss		
						ᆚ

Examiner	Date	12/01/2010
Signature	Considered	12/01/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitu	te for form 1449B/PTO			Complete if Known		
				Application Number	09/724,685	
INF	ORMATION DISC	21.09	SURF	Filing Date	11-28-2000	
	STATEMENT BY APPLICANT			First Named Inventor	Steven G. Reed	
317	ALEMENT DI AF	FLIC	ANI	Art Unit	1645	
(Use as many sheets as necessary)		Examiner Name	Rodney P. Swartz			
Sheet	21	of	32	Attorney Docket Number	GSK006C13/CRX411C13	

		NON PATENT LITERATURE DOCUMENTS	
Examin er Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	290	ROSENFELD, et al., "Adenovirus-Mediated Transfere of a Recombinant Alpha-1 Antitrypsin Gene to Lung Epithelium in Vivo," Science 252:431-434 (1991)	
	291	ROSSOLINI, et al., "Use of deoxyinosine-containing primers versus degenerate primers," Mol. Cell. Probes 8:91-98 (1994)	
	292	SATO, et al., "Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization," Science 273:352 (1996)	
	293	SCHARF, et al., "Heat Stress Promoters and Transcription Factors," Results Probl. Cell Differ. 20:125-162 (1994)	
	294	SINGH, et al., "In Vitro Characterization of T Cells from Mycobacterium W-Vaccinated Mice," Infection and Immunity 60(1):257-263 (1992)	
	295	SINHA, et al., "Immunological properties of a 30 Kda secretory protein of Mycobacterium tuberculosis H37RA," Vaccine 15(6-7): 689-99 (1997)	
	296	SIMONNEY, et al., "Analysis of the immunological humoral response to Mycobacterium tuberculosis glycolipid antigens (DAT, PGLTb1) for diagnosis of tuberculosis in HIV-seropositive and seronegative patients," Eur. J. of Clin. Microbiology and Infectious Disease 14(10):883-891 (1995)	
	297	SKEIKY, et al., "LeIF:a recombinant leishmania protein that induces an IL-12 mediated Th cytokine profile," J. of Immunology 161: 6171-79 (1998)	
	298	SKEIKY, et al., "Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein," J. of Immunology 172(12):7618-28 (2004)	
	299	SKORKO-GLONEK, "Comparison of the structure of wild-type HtrA heat shock protease and mutant HtrA proteins. A Fourier transform infrared spectroscopic study," JBC 270(19): 11140-11146 (1995)	

Examiner	Date	12/01/2010
Signature	Considered	12/01/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitu	ite for form 1449B/PTO			Complete if Known		
				Application Number	09/724,685	
INFORMATION DISCLOSURE				Filing Date	11-28-2000	
	ATEMENT BY AP			First Named Inventor	Steven G. Reed	
317	AIEMENI DI AF	FLIC	JANI	Art Unit	1645	
(Use as many sheets as necessary)		Examiner Name	Rodney P. Swartz			
Sheet	22	of	32	Attorney Docket Number	GSK006C13/CRX411C13	

		NON PATENT LITERATURE DOCUMENTS	
Examin er Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	300	SKUCE, et al., "Discrimination of M. tuberculosis complex bacterial using novel VNTR-PCR targets," Microbiology 148(2):519-28 (2002)	
	301	STOUTE, et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against Plasmodium Falciparum Malaria," New Engl. J. Med. 336:86-91 (1997)	
	302	TIMMERMAN and LEVY, "Dendritic Cell Vaccines for Cancer Immunotherapy," Ann. Rev. Med 50: 507-529 (1999)	
	303	TRIGLIA, et al., "A Procedure for In Vitro Amplification of DNA Sequences that Lie Outside the Boundaries of Known Sequences," Nucl. Acids Res. 16:8186 (1988)	
	304	TSENOVA, et al., "Evaluation of the Mtb72F Polyprotein Vaccine in a Rabbit Model," Infection and Immunity 74(4):2922-401 (2006)	
	305	ULMER, et al., "Heterologous Protection Against Influenze by Injection of DNA Encoding a Viral Protein," Science 259:1745-1749 (1993)	
	306	VAN PITTIUS, et al., "Evolution and expansion of the M. tuberculosis PE and PPE multigene families and their association with the duplication of the ESAT-6 (esx) gene cluster regions," BML Evolutionary Biology 6(1):95 (2006)	
	307	VEKEMANS et al., "Immune Responses to Mycobacterial Antigens in the Gambian Population,", Infection and Immunity 72(1):381-88 (2004)	
	308	VON ESCHEN, et al., "The candidate tuberculosis vaccine Mtb72F/AS02A," Human Vaccines 5(7):475-82 (2009)	
	309	VERBON, et al., "The 14,000-Molecular-Weight Antigen of Mycobacterium tuberculosis Is Related to the Alpha-Crystallin Family of Low-Molecular-Weight Heat Shock Proteins," J. of Bacteriology 174(4):1352-1359 (1992)	

Examiner	Date	12/01/2010
Signature	Considered	12/01/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitu	ite for form 1449B/PTO			Complete if Known		
				Application Number	09/724,685	
INFORMATION DISCLOSURE				Filing Date	11-28-2000	
	ATEMENT BY AP			First Named Inventor	Steven G. Reed	
317	AIEMENI DI AF	FLIC	AINI	Art Unit	1645	
(Use as many sheets as necessary)		Examiner Name	Rodney P. Swartz			
Sheet	23	of	32	Attorney Docket Number	GSK006C13/CRX411C13	

		NON PATENT LITERATURE DOCUMENTS	
Examin er Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	310	VORDEMEIER, et al., "Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles," Vaccine 13(16):1576-1582 (1995)	
	311	WALLIS, et al., "Identification of Antigens of Mycobacterium tuberculosis Using Human Monoclonal Antibodies," J. Clin. Invest. 84:214-219 (1989)	
	312	WANG, et al., "Tuberculosis Vaccines: Past, Present and Future," Expert Rev. Vaccines 1(3):341-54 (2002)	
	313	WANG, et al., "A novel method for increasing the expression level of recombinant proteins," Protein Expression and Purification 30(1):124-133 (2003)	
	314	WEBB, et al., "Molecular Cloning, Expression and Immunogenicity of MTB12," Infection & Immunity 66(9):4208-4214 (1998)	
	315	WIEGESHAUS, et al., "Evaluation of the protective potency of new tuberculosis vaccines," Reviews of Infectious Diseases 11(Suppl. 2):S484-S490 (1989)	
	316	WIGLER, et al., "Transformation of mammalian cells with an amplifiable dominant-acting gene," PNAS USA 77:3567-70 (1980)	
	318	WIKER and HARBOE, "The Antigen 85 Complex: a Major Secretion Product of Mycobacterium tuberculosis," Microbiological Reviews 56(4):648-661 (1992)	
	319	WINTER, "The Expression of Heat Shock Proteins and Cognate Genes During Plant Development," Results Probl. Cell Differ. 17: 85-105 (1991)	
	320	ZIMMERMAN, et al. "Immunization with peptide heteroconjugates primes a T helper cell type 1-associated antibody (IgG2a) response that recognizes the native epitope on the 38-kDa protein of Mycobacterium tuberculosis," Vaccine Res. 5(2):103-118 (1996)	

Examiner	Date	12/01/2010
Signature	Considered	12/01/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it displays a valid OMP control purpose.

Substitute for form 1449B/PTO				Complete if Known		
				Application Number	09/724,685	
INF	ORMATION DISC	SI 09	SURF	Filing Date	11-28-2000	
STATEMENT BY APPLICANT				First Named Inventor	Steven G. Reed	
				Art Unit	1645	
(Use as many sheets as necessary)			ı	Examiner Name	Rodney P. Swartz	
Sheet	24	of	32	Attorney Docket Number	GSK006C13/CRX411C13	

	NON PATENT LITERATURE DOCUMENTS					
Examine r Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
	321	ZITVOGEL, et al., "Eradiation of established murine tumors using a novel cell-free vaccine: dedritic cell-derived exosomes," Nature Med. 4:594-600 (1998)				
	322	Seq_NCBI_AL021930.1, 2 pages 2003				
	323	Seq_NCBI _ AL021930, 17 pages 2003				
	324	Seq_Accession No. O05907, Database:stpremb119, publicly available Jul. 1, 1997				
	325	Seq_Accession No. O05908, Database:stpremb119, publicly available Jul. 1, 1997				
	326	Seq_ EMBL _ MTCY7H7Bc, Accession No. Z95557, May 20, 1997				
	327	Seq_ EMBL _ MTCY24G1, Accession No. Z83858, Jan. 13, 1997				
	328	Seq_ EMBL _ MTCY19G5, Accession No. Z77826, Jul. 31, 1996				
	329	Seq_EMBL _ MTCY261, Accession No. Z97559, Jul. 10, 1997				
	330	Seq_ EMBL _ Z78020, XP002224823 2003				

Examiner	Date	12/01/2010
Signature	Considered	12/01/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO				Complete if Known		
				Application Number	09/724,685	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	11-28-2000	
				First Named Inventor	Steven G. Reed	
				Art Unit	1645	
(Use as many sheets as necessary)			ı	Examiner Name	Rodney P. Swartz	
Sheet	25	of	32	Attorney Docket Number	GSK006C13/CRX411C13	

NON PATENT LITERATURE DOCUMENTS					
Examine r Initials*	Citq No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	331	Seq_EMBL_P41403, XP002224824 2000			
	332	Seq_ EMBL _ Q50596, XP002224822 2000			
	333	Seq_ EMBL _ Z17372, XP002224825 2000			
	334	Seq_ EMBL _ U90239, XP002224826 2000			
	335	Seq_ EMBL _ P97048, XP002224827 2000			
	336	Seq_Accession_No_AU077540 2000			
	337	Seq_EMBL _P15712, (1990-04-01) "PBP-1 from M. tuberculosis" XP002359448			
	338	Seq_Uniprot _ Q79FV1 2000			
	339	Seq_Uniprot _ O06267 2000			
	340	Seq_Uniprot _ P96364 2000			

Examiner Signature /Rodney P. Swartz, Ph.D./	Date Considered	12/01/2010
--	--------------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.